Date: 2015-01-22
Type of information: Nomination
Compound:
Company: Ariad Pharmaceuticals (USA - MA)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 22, 2015, Ariad Pharmaceuticals announced the appointment of Thomas J. DesRosier, Esq. to the position of executive vice president, chief legal and administration officer, and secretary. Mr. DesRosier will be responsible for global legal operations, information technology and other administrative functions. He will report to Ariad’s chairman and chief executive officer, Harvey J. Berger, M.D. Mr. DesRosier has more than 30 years of global biotechnology and pharmaceutical industry experience and joins Ariad from Cubist Pharmaceuticals, Inc., where he held the same position as the one he will assume at Ariad. Prior to Cubist, Mr. DesRosier was senior vice president, general counsel, North America of Sanofi, a position he assumed following the acquisition of Genzyme Corporation by Sanofi in 2011, where he had served as Genzyme’s senior vice president, chief legal officer.
Financial terms:
Latest news:
